BSE filing, NSE: ARIHANTCAP. Summary written from the filing by ALFA Finder's alert engine.
Arihant Capital Markets Ltd: key numbers
- Share price
- ₹86.68
- Market cap
- ₹950.1 Cr
- Revenue (annual)
- ₹205.8 Cr
- Net profit (annual)
- ₹31.46 Cr
- P/E (TTM)
- 23.6×Sector 19.1×
- Promoter holding
- 67.67%+0.00% QoQ
- FII holding
- 0.10%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Arihant Capital Markets Ltd
All →Arihant Capital Markets Board Meeting Date
Arihant Capital Markets will hold a board meeting on 30-Oct-2026 to consider unaudited standalone and consolidated results for the quarter and half year ended 30-Sep-2026. The trading window is closed from 01-Oct-2026.
Arihant Capital Markets Other Announcement
Arihant Capital Markets Ltd submitted its quarterly shareholding pattern report for the period ended September 30, 2026, as required under SEBI regulations.
Arihant Capital Markets Annual General Meeting
Arihant Capital Markets Ltd held its 34th Annual General Meeting, approving financial statements for FY2026 and declaring a dividend of Rs. 0.50 per share.
Arihant Capital Markets Annual General Meeting
Arihant Capital Markets Limited issued notice for its Annual General Meeting scheduled for 26-Sep-2026. Shareholders will consider financial statements, dividends, and director re-appointment.
Arihant Capital Markets Annual Report
Arihant Capital Markets Limited has submitted its Integrated Annual Report for the fiscal year 2025-26 along with the notice for its 34th Annual General Meeting.
Arihant Capital Markets Dividend
Arihant Capital Markets fixed September 19, 2026, as the record date for a proposed 50% final dividend. The 34th AGM is scheduled for September 26, 2026.
Other regulatory approval announcements
All →Vedavaag Systems Regulatory Approval
Vedavaag's WOS received IRDAI Certificate of Registration to act as Direct Life & General Insurance Broker. The group enters regulated insurance broking activity.
Hikal Regulatory Approval
Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
RNFI Services Regulatory Approval
RNFI received RBI no-objection to acquire control of Smart Payment Solutions Private Limited. Remaining tranches may proceed, but no transaction value is disclosed.
Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.